Lilly To Acquire Injectable Mfg Site From Nexus Pharma

Eli Lilly and Company has agreed to acquire a manufacturing facility in Pleasant Prairie, Wisconsin, from Nexus Pharmaceuticals, a Lincolnshire, Illinois-based specialty- and generic-drug manufacturer of injectable drugs.  

Lilly estimates that production at this facility could begin at the end of 2025. The facility does not provide contract manufacturing services, thereby allowing the facility to be solely dedicated to Lilly’s manufacturing. 

The facility will expand Lilly’s global parenteral (injectable) product manufacturing network and is the latest in series of manufacturing investments announced by Lilly.  

Last November (November 2023), the company announced plans to construct a new $2.5-billion injectable manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company’s global parenteral (injectable) product and device manufacturing network and support increased demand for Lilly’s medicines, including its diabetes and obesity drug portfolio. Construction is scheduled to begin in 2024, and the new site is scheduled to be operational beginning in 2027.  

In addition, in April 2023, Lilly announced that it will invest an additional $1.6 billion at its two new manufacturing sites within the LEAP Innovation Park in Boone County, Indiana. In May 2022, Lilly announced a $2.1-billion investment to build the two new facilities to expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, such as genetic medicines. The now combined $3.7-billion investment represents the largest manufacturing investment at a single location in the company’s history.   

Also, in 2023 (March 2023), Lilly broke ground on a new $1-billion biotech manufacturing campus in Raheen, County Limerick, Ireland, which will be Lilly’s most advanced manufacturing site for existing monoclonal antibodies. This site will produce existing products as well as the company’s pipeline of clinical products by 2026. Additionally, the company plans to invest $500 million in Limerick to create a new biologics active ingredients site. The new $1.5-billion combined investment in Ireland is in addition to an $1-billion investment that the company announced in January 2022, for a new injectable products and devices manufacturing site in Concord, North Carolina.    

Source: Nexus Pharmaceuticals and  Eli Lilly and Company